The document is a cost approval request for HyQvia®, a human immunoglobulin therapy, to be submitted to the health insurance under Article 71a-d KVV. The request includes coverage for HyQvia® and associated infusion equipment.

The document details the support offered by various Homecare Services for patients treated by subcutaneous immunoglobulin therapy. It also provides contact information for different homecare providers throughout Switzerland, emphasizing their availability and communication channels. 

The 20th edition of the European Crohn's and Colitis Organisation (ECCO) Congress in Berlin was a complete success!

HyQvia® is an immunoglobulin solution for subcutaneous application. Facilitated by recombinant human protein hyaluronidase, immunoglobulin absorption and bioavailability will be improved, allowing for the application of high immunoglobulin volumes. Thus, HyQvia® can be applied once or twice monthly at home.

Cuvitru® is a 20% immunoglobulin solution for subcutaneous application at home.